

CERTIFICATE

Survey of 29 May 2019

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 13 - LMW Heparin (281):

Validity 12 months:

Low mol. weight Heparin

Haemostasis 22 - Dabigatran (502):

Validity 12 months:

Dabigatran

Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

Haemostasis 25 - Apixaban (504):

Validity 12 months:

Apixaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek

Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2



Düsseldorf, 01 July 2019

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE

Survey of 29 May 2019

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 32 - Edoxaban (505):

Validity 12 months:

Edoxaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek

Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 01 July 2019



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE

Survey of 29 May 2019

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 01 - TPT, INR, aPTT (221):

Validity 6 months:

TPZ INR (R: B1a)

aPTT (R: B1a)

Haemostasis 02 - FIB, TZ, FSP (222):

Validity 12 months:

Fibrinogen

Thrombin Time

Haemostasis 05 - AT, Protein C, Protein S, C1-Inhibitor (225):

Validity 12 months:

Antithrombin

free Protein S funct. (act.)

total Protein C

Haemostasis 06 - D-Dimer (226):

Validity 12 months:

D-Dimer (qual)

D-Dimer (quant.)

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek

Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2



Düsseldorf, 01 July 2019

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

CERTIFICATE

Survey of 29 May 2019

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 07 - Factor VIII, WF (227):

Validity 12 months:

Faktor VIII akt.

Willebrand Fact. Ag

Willebrand Fact. RiCof

Haemostasis 20 - Functional APC Resistance (288):

Validity 12 months:

diagnostic comments

(R) analysis is subject to the RiliBAK

Participant:

2430

MUDr., PhD. Martin Spacek


Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratorie ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 01 July 2019



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

